

1 **HIV testing intervention development amongst MSM in the developed world**

2 Flowers. P¹., Estcourt, C²., Sonnenberg, P³ and Burns, F^{3,4}.

3

4

5

6

7 **Affiliations:**

8

9 ¹ Institute for Applied Health Research, Glasgow Caledonian University , Scotland, UK

10 ² Blizard Institute, Barts and the London School of Medicine and Dentistry, Barts Sexual
11 Health Centre, UK

12 ³ Research Department of Infection & Population Health, University College London,
13 UK

14 ⁴ Royal Free London NHS Foundation Trust, UK

15

16

17

18

19 **Corresponding author**

20 Paul Flowers

21

22 Email: P.Flowers@gcu.ac.uk

23

24 **HIV testing intervention development amongst MSM in the developed world**

25 Abstract

26

27 HIV testing is a ‘gateway’ technology – enabling access to treatment and HIV prevention.
28 Biomedical approaches to prevention, such as Pre-exposure prophylaxis (PrEP) and
29 Treatment as prevention (TasP), require accurate and regular HIV test results. HIV testing
30 also represents a powerful ‘teachable moment’ for behavioural prevention. An increasing
31 range of HIV tests and the emergence of self-managed diagnostic technologies (e.g., self-
32 testing) means there is now considerable diversification of when, where, how results are
33 available to those who test. These changes have profound implications for intervention
34 development and indeed health service redesign. This paper highlights the need for better
35 ways of conceptualizing testing in order to capitalize on the health benefits that diverse HIV
36 testing interventions will bring. We propose a multidimensional framework to capture on-
37 going developments in HIV testing amongst MSM. We focus on the intersection of i) the
38 growing variety of HIV testing technologies and the associated diversification of their
39 pathways into care, ii) psychosocial insights into the behavioural domain of HIV testing, iii)
40 better appreciation of population factors associated with heterogeneity and concomitant
41 inequities. We propose that by considering these three aspects of HIV testing in parallel, it is
42 possible to identify gaps, limitations and opportunities in future HIV testing-related
43 interventions. Moreover, it is possible to explore and map how diverse interventions may
44 work together having additive effects. We believe that only a holistic dynamic framework
45 that captures the increasing complexity of HIV testing can deliver the maximum public health
46 benefit of HIV testing for 2020.

47

48

49

50 HIV testing intervention development amongst MSM in the developed world

51

52 **Background**

53 We propose that HIV testing has become *the* central health technology for HIV prevention
54 for both those testing positive and negative. Pre-exposure prophylaxis (PrEP) and wider
55 treatment as prevention (TasP) highlight the growing challenges of understanding the
56 relationship between condom-less sex and HIV transmission risk. The value of condom use
57 as the primary focus of prevention and behavioural surveillance is rapidly diminishing
58 particularly in countries where PrEP is available. We suggest that HIV testing now supersedes
59 condom use as the behavioral focus of future HIV prevention interventions amongst MSM in
60 the developed world. Testing presents a relatively future-proof ‘common denominator’ an
61 ever-diversifying portfolio of prevention approaches implemented in different ways across
62 national settings. HIV prevention approaches which rely on HIV testing range from PrEP
63 (which requires accurate and regular HIV testing), across the cluster of behavioural
64 interventions based around sero-status (including sero-sorting and partner notification
65 interventions), to more psychological interventions in which testing may represent a
66 ‘teachable moment’ (by using HIV status to galvanize the adoption and commitment to
67 behavior change.¹ Wherever treatments are widely available, HIV incidence is likely to be
68 driven by the undiagnosed fraction of people living with HIV and most HIV morbidity and
69 mortality is increasingly associated with late diagnosis^{2,3}. There is a growing need to
70 recognize the central part HIV testing plays in diverse prevention interventions.

71

72 Because HIV testing sits at the nexus of a range of approaches to prevention and care it has
73 been the focus of both increased international scrutiny^{4,5,6} and product development win

74 the commercial sector. At its core, all HIV testing remains fundamentally concerned with
75 diagnosis (see Table 1 for an overview of the function of HIV testing). However, recent
76 innovations have focused on developing diversity in the processes that accompany this
77 central diagnostic function. Variations for example, in the ability to detect recently acquired
78 infections, who administers the test, how long to wait for the test results, the ways in which
79 test results are delivered and the combination of other tests which may accompany the HIV
80 test (e.g., tests for other sexually transmitted infections (STI) and blood borne viruses (BBV)).
81 Perhaps associated with the focus on HIV testing as a preventative technology, and in
82 relation to the economic context of HIV service delivery in much of the developed world,
83 there has also been a marked turn towards the self-management of HIV testing in recent
84 years, for example self-testing and self-sampling.

85

86 These approaches differ in that in self-testing the testee receives and interprets the result
87 themselves in minutes of testing themselves. In contrast, in self-sampling, the testee collects
88 their sample but then sends the kit away to another setting where a professional interprets
89 the results and contacts the testee with their test result some time later. This move to self-
90 managed testing has happened at the same time as a notable historical and cultural shifts in
91 both the economic context of much of the developed world and in the mediation of MSMs'
92 sexual cultures away from solely physical worlds to embrace intersections with the digital
93 world (e.g., the availability of the test through internet sites or mobile phone apps).⁷ In this
94 way testing interventions in general, and self-managed testing interventions in particular,
95 are increasingly being delivered on-line and outwith traditional 'bricks and mortar' services.
96 In many national contexts, from the perspectives of those who are testing, direct contact
97 with health professionals administering the test or sharing test results is reducing.

98

99 Over the short history of the HIV epidemic many different disciplines have focused on HIV
100 testing highlighting considerable behavioral, social and historical variation. Since effective
101 antiretroviral therapies have become available, there has been a shift in thinking of the HIV
102 test as a relatively infrequent, one-off event, perhaps confirming suspected HIV status, to
103 ideas associated with the HIV treatment cascade and getting people living with HIV on
104 treatment as quickly as possible to minimize harm to their immune system and reduce
105 population viral load.⁸ Equally, since the ‘normalization’ of HIV testing⁹ there has been a
106 change in considering those who test frequently, from being pathological ‘repeat testers’
107 (with pejorative associations and assumptions relating to on-going problematic behavior) to
108 focusing more on the salutogenic aspects of those people who test regularly. People who
109 test regularly minimize HIV transmission risk and their accurate test results scaffold
110 biomedical approaches such as PrEP.

111

112 In light of these technological, social and historical changes and the profusion of
113 technologies, choices, processes, and behaviors associated with HIV testing, we believe it is
114 no longer useful to talk about HIV testing interventions or HIV testing policy in any unitary
115 or simplistic fashion. There will be no single testing intervention that represents a panacea
116 to the on-going problems of HIV prevention in any single population such as MSM. It is highly
117 likely that multiple testing interventions, delivered simultaneously to different populations
118 at different times may offer the most sustainable and effective ways of preventing HIV
119 transmission. There is a growing need for clarity and shared language in thinking about HIV
120 testing and to acknowledge the increasing heterogeneity of testing. We believe that in order
121 to deliver the best of what HIV testing can offer to HIV prevention we need to understand

122 HIV testing in multidimensional ways that capture key differences in technology, behavioural
123 domain and population. In this way it is possible to consider the tailoring and targeting of
124 diverse HIV testing interventions enabling much better purchase on issues such as
125 effectiveness and cost-effectiveness. In this way, further clarity regarding the heterogeneity
126 of HIV testing interventions will enable us to develop cumulative knowledge and make more
127 use of existing evidence.

128

129 **Table 1 about here**

130

131 **The growing variety of HIV tests and the diversification of pathways into care**

132 The first commercially available HIV test, an enzyme-linked immunosorbent assay (ELISA)
133 test, entered the market in 1985. It was a blood-based test that often took two weeks before
134 results were available. As no effective treatment existed all testing was accompanied by
135 extensive pre and post-test counselling and was primarily conducted in the domain of HIV
136 ‘specialist centres’ or blood banks. Although identifying primary HIV infection was not a
137 prime focus then, the window period, the term given to the maximum time between HIV
138 virus acquisition and the ability of the test to detect the infection, would have been three
139 months. Since then the implications of a positive diagnosis have changed dramatically, and
140 that, coupled with the expansion of testing modalities, has enabled HIV testing to move
141 beyond the remit of specialists into the broader health community and finally directly into
142 the control of the end user. Table 2 provides an overview of the increasingly diverse range
143 of tests currently available and many of their key features. The first home testing kit was
144 actually licensed in the USA in 1996. However scale up of testing beyond traditional health
145 care settings has been evolving from solely being offered within traditional testing services,

146 to a wider range of settings (such as within community settings or sex on premises testing
147 sites). This trend of increasing testing sites has been further expanded following recognition
148 of the key role undiagnosed infection has in potentiating HIV transmission ¹⁰ and because
149 biomedical prevention interventions have been shown to be so effective. ⁸ International
150 findings suggest linkage to care may be influenced by site of diagnosis, with people testing
151 positive in community setting, as opposed to clinic and other formal health care settings,
152 being less likely to be linked into and retained in care.¹¹ In the UK, preliminary data from the
153 national self-sampling pilot does suggest that only 77.4% of people with reactive tests are
154 linked to care for confirmatory testing¹². The relative benefit of these innovations (in that
155 they may reach new populations) is offset by higher attrition in the cascade of care. Equally
156 the psychological impact of living with an incorrectly assumed HIV positive status is unknown
157 and for positive people who do not start treatment there are on-going risks to their own
158 health and increased risks of onwards transmission.

159

160 Testing options accessible via the Internet may be cheaper to provide and from the testee's
161 perspective may avoid the need to access sexual health services which can be inconvenient
162 and stigma laden. Equally the use of any face-to-face testing service may raise fears around
163 confidentiality for some MSM who may not have disclosed their sexual conduct with other
164 men to a health care professional. Equally digital options to access testing will be avoided by
165 those who value the more holistic care received via face-to face interventions (see section
166 below). Service providers also value choice, and the range of testing modalities enables
167 provision of tests best suited to their practice and the presentation of individual cases. Point
168 of care tests are used routinely in sexual health services, however Primary Care clinicians
169 may feel they lack the infrastructure or service flexibility to manage the unexpected reactive

170 results and prefer instead methods where they have more control of when and how to
171 deliver results. Currently in the UK, the only self-managed testing options on the market are
172 3rd generation tests which makes them less suitable for detecting recently acquired
173 infections than fourth generation tests which are not available through self-managed routes.
174 For MSM this current state of affairs limits the usefulness of self-testing in diagnosing very
175 recent infection.

176

177 **Table 2. around here**

178

179 **Psychosocial insights into the behavioural domain of HIV testing**

180 There have been problems with attempts to synthesize evidence regarding the role of HIV
181 testing in relation to risk behavior with inconsistent accounts of the relationship between
182 testing and sexual behavior change.^{13, 10} Arguably, these problems relate primarily to a lack
183 of attention to the historical, social and psychological heterogeneity of HIV testing
184 behaviours and a rather unitary focus on the test's diagnostic function. At the population
185 level, in many countries, HIV testing has changed over time, with increases reported
186 particularly amongst high-risk populations such as MSM.^{14, 15} These trends reflect changes in
187 the meaning of HIV testing for example in light of ART and PrEP. Currently, for example,
188 people may seek HIV testing in order to access treatment for HIV infection, or conversely to
189 access PrEP to avoid HIV infection. Equally, more psychologically, for the individual, across
190 *their* life span and in relation to their sexual careers, HIV testing can mean very different
191 things. Deeper understandings of the behavioural domains of HIV testing (e.g., the range of
192 testing behaviours and their associated antecedents) and specificity in relation to measuring
193 HIV testing (e.g., how often and for what reason) may enable more useful attempts to build
194 cumulative knowledge in relation to HIV testing in order to develop new conceptual and
195 analytic approaches to data analysis, evidence synthesis and future intervention
196 development. In the sections below and within Table 3 we explore from a psychological
197 perspective the importance of the psychosocial, technical and temporal context of HIV
198 testing.

199

200 *The psychosocial context of HIV testing behaviours*

201 Understanding and responding to the psychosocial aspects of HIV testing is vital to develop
202 a range of behavioural interventions in the future. In the UK for example on a population

203 level, HIV risk perception is low. Most people who perceive themselves as at risk of HIV have
204 not recently tested, including MSM. ¹⁶ Population level social epidemiology regarding HIV
205 testing, with its focus on population means, fails to appraise the heterogeneity of testing
206 from the perspectives of those seeking or indeed being offered a test. For the individual
207 person seeking an HIV test there are differences in the meaning of HIV testing depending on
208 their perception of the likelihood, and the implications of, a positive diagnosis for them at
209 that time in their life. Fear of a positive test result remains a major barrier to seeking HIV
210 testing and this is patterned by perceived likelihood of positive results¹⁷. Testing following a
211 perceived risk event, for example, is considerably different from testing which is regular or
212 habitual. It may present very different psychological processes than those that preceded an
213 individual's previous HIV tests. Testing that was initiated by a health professional, for
214 example, may have required little conscious thought or decision-making for the person
215 getting tested. Increasing testing such as this can be achieved through interventions that
216 focus upon increasing opportunities for these kinds of interactions. In contrast, following
217 perceived risk events, interventions may be more effective if they focus on the deliberate,
218 pro-active, reflective decision-making to seek, or to avoid, an HIV test (akin to 'opt-in'
219 testing).

220

221 In this way even a superficial exploration of the psychosocial context of HIV testing
222 behaviours highlights the need for diverse approaches to testing interventions in
223 relationship to their target population (e.g., patient vs healthcare or community worker),
224 their mechanism of action (e.g., capability approaches vs motivational approaches),
225 anticipated positivity (e.g., high vs low), cost effectiveness (e.g., tolerance for high resource
226 per test vs low) and the selection of testing technology according to the immediacy of

227 receiving test results (e.g., rapid vs slower pace) and the location in which a person prefers
228 testing to take place (e.g., if it's a routine, expected-to-be-negative test, home testing may
229 be appropriate but if positive results are expected, a person may well want to test where
230 face to face support and access to holistic care is readily available).

231

232 *Technological contexts of testing behaviour*

233 As the previous section described, technological variation in HIV testing is growing. This
234 brings with it increases in the choice of testing but also an increase in the scope and
235 complexity of what the respective tests demand from both the testee and the test provider.
236 Increasing choice of test is important as it relates to potential reductions in barriers to testing
237 by increasing opportunities to test and enables the tailoring of different tests to specific
238 psychosocial, cultural or service-provision contexts. We believe facilitating choice in tailoring
239 testing technology represents a novel and viable locus of intervention development for
240 MSM.

241

242 Interventions that focus upon choice and increasing opportunities to test must also address
243 issues of capability as different tests demand different levels of skills, health literacy and in
244 some national contexts material resources. With regard to self-managed tests, dry blood
245 spot approaches demand a distinct behavioral repertoire (i.e. drawing and managing blood
246 samples) when compared to those associated with tests that use saliva for example. Equally,
247 online ordering of test kits to be delivered to the home requires a set of different skills,
248 behaviours and resources than those needed to travel to a testing site, book appointments
249 and interact with a health professional. The interplay of psychosocial issues with the demand
250 dimensions of the range of testing technologies remains under explored, yet vital to

251 harnessing future HIV testing interventions. It also highlights the importance of attending to
252 health, social and economic inequalities and the structural determinants of testing. The
253 heterogeneity of health care contexts, and the varying accessibility of the range of testing
254 approaches across national settings provide an interesting natural experimental design for
255 monitoring choice-based testing interventions.

256

257 *Temporal contexts*

258 The historical nature of evidence concerning HIV testing interventions may limit its
259 transferability to current contexts. However, we would argue it is also important to focus
260 upon the temporal aspects of an individual and what could be termed their testing career.
261 The utility of population-level testing surveillance will be increasingly compromised if the
262 temporal dimensions of individual testing patterns are not adequately addressed. The
263 effectiveness of ART in reducing transmission amongst those living with HIV and those who
264 take PrEP has stressed the importance of considering the temporal dimensions of HIV testing
265 in the life context. Only test results that accurately reflect recent infection, or lack of
266 infection, are useful to enable these biomedical preventative approaches. Older ways of
267 thinking about testing that centred on diagnosis and access to treatment alone increasingly
268 limit our thinking of testing interventions. This vestigial thinking which focuses upon the
269 dichotomy and durability of positive and negative test results, limits our insights into the
270 undiagnosed fraction of positive people, especially in those who have had a previous
271 negative HIV test result¹⁸. Measurement tools, data analysis, and lay understandings often
272 continue to focus on the dichotomy of 'ever vs never' tested rather than focusing on testing
273 rates amongst those at on-going risk. Equally studies which conflate recency of testing with
274 regularity of testing obscure the focus on regular, time-bound, repeat testing as a key

275 behavioural goal necessary for fully utilizing HIV testing for 2020. A deeper understanding of
276 the frequency of testing, or inter test intervals is required ¹⁹ to consolidate testing
277 interventions for the future. Behavioural interventions must focus on specific aspects of the
278 HIV testing domain (for example, in the UK targeting frequent self-sampling approaches
279 amongst MSM at high risk (e.g., every 12 weeks) rather than annual testing through self-
280 testing amongst the whole MSM population).

281

282

283 Table 3 around here

284

285 **Population factors: the heterogeneity of the MSM population and associated inequities**

286 Social epidemiology tends to aggregate groups of people at the population level, for
287 example, in the UK 'MSM' vs 'Black African' as two primary populations at most risk of HIV.

288 However, an appreciation of the heterogeneity of the MSM population in relation to HIV
289 testing, across a range of dimensions, may lead to effective targeting of limited resources.

290 As evidence of effectiveness of testing interventions develops, sub-population specificity, or
291 concerns about transferability in the MSM population should be systematically highlighted.

292 This 'granular' understanding of the MSM population would enable consideration of a range
293 of simultaneous testing interventions each addressing specific sub-populations, this enables

294 consideration of developing testing interventions in relation to inequalities and the social
295 determinants of testing. Such a pluralistic approach to understanding MSM and diverse

296 testing interventions may ensure that testing interventions do not amplify health inequities
297 in the MSM population as a whole. Instead a range of acceptable and effective testing

298 interventions could be available which can be tailored via user preference, capability and
299 sub-population specificity. Considerations of population segmentation highlight the

300 stratification of effectiveness and cost-effectiveness. In as much as what works for one group
301 of men (e.g., those that use the internet and phone apps regularly) may not work for others

302 (MSM in rural communities with no 4G coverage), or indeed for the MSM population as a
303 whole (e.g., social marketing or mass media approaches ²⁰). Furthermore, sub-population

304 segmentation illuminates cost effectiveness in relation to those that can only be reached by
305 particularly expensive interventions.

306

307 *Focus on barriers to testing*

308 Barriers to testing represent a key way of considering population specificity. Amongst those
309 who can acknowledge their vulnerability to HIV infection, grouping individuals according to
310 their perceived barriers to testing can enable a useful and tailored repertoire of testing
311 interventions. Targeting motivation-based testing interventions which focus on persuading
312 those who are fearful of testing need to be distinct from opportunity-based interventions
313 which target people who wish to seek testing but struggle to utilize current testing provision
314 for example. Equally, where testing is readily available, not testing may also relate to a failure
315 to recognize risk exposure¹⁶ thus highlighting the need for educational approaches delivered
316 to the whole population for example. These different intervention targets demand
317 interventions with different mechanisms of action and different modes of delivery.

318

319 *Lifespan perspectives*

320 Key differences exist in relation to testing with regard to a persons' life context. These are
321 reflected the international literature demonstrating strong positive correlations between
322 age and testing²¹. Irrespective of perceived risk, testing for the first time may be associated
323 with increased anxiety when compared to repeat, habitual or routine testing later within
324 sexual careers (e.g., as a necessary precursor to accessing PrEP). These lifespan perspectives
325 may offer purchase to designing particular interventions for particular groups, for example,
326 considering targeted interventions for young MSM that fostered routine testing behaviours
327 (including HIV) coupled with HPV vaccination for example or a focus on MSM in
328 relationships²²

329

330 *Health and digital literacy*

331 Many of the preceding sections have touched on issues relating to health literacy, for
332 example, the ability to recognize prior or potential risk through an understanding of the
333 sometimes-complex factors associated with HIV transmission. Addressing issues of health
334 literacy is likely to be of fundamental importance to consolidating the opportunities available
335 for HIV testing interventions²³ Equally, the various testing technologies available present a
336 range of user demands differentially requiring degrees of literacy, numeracy and manual
337 dexterity. Moreover, as some of the self-managed tests lend themselves to digital
338 distribution it is important to acknowledge that whilst this approach removed barriers for
339 some (those seeking to test in rural areas with little alternative testing provision for example)
340 it may create barriers for others²⁴. Such approaches necessitate a viable Internet connection
341 and assume material and technical resources in order to be effective. In this way, even at a
342 rural population level, whilst on-line self-testing interventions may prove a pragmatic and
343 effective way of increasing testing they are likely to so do only in a specific sub-population
344 (those with digital literacy a particular level of material and technological resources). They
345 may poorly serve those who may need HIV testing most.

346

347 *Intersectionality, syndemics and social vulnerability*

348 Finally, it is important to consider the specificity of sub-populations by traditional socio-
349 demographic features and their intersections. The particular vulnerabilities of black and
350 minority ethnic MSM are well documented in some national contexts ^{25, 26, 27, 28} Yet how
351 these vulnerabilities intersect with other important markers such as age and poverty are not
352 well documented. Equally, the relationship between vulnerabilities and testing technology
353 and the behavioural domain of HIV testing remain under explored to date.

355 Table 4 around here

356

357 **Discussion**

358 If we are to maximize the individual and public health benefits presented by HIV testing
359 interventions we must think beyond the HIV test's diagnostic function and consider the
360 technological, psychosocial and sociocultural contexts of HIV testing. The increasing
361 diversification of the tests available demand systematic consideration of the right test for
362 particular circumstances and particular sub-populations and recognize that over time the
363 same person may well require different testing methods & settings. This multidimensional
364 understanding of HIV testing will be important for patient preference, yet scaled up, it is
365 equally important for considering the distribution of resources to support intervention
366 design and indeed to make the most of available evidence detailing the effectiveness of
367 testing intervention.

368

369 There is a danger that by not grasping the complexity of HIV testing and harnessing its
370 emerging pluralities, that we only reach the low hanging fruit; designing, evaluating and
371 implementing testing interventions that work for limited groups of people but do not impact
372 on the actual drivers of HIV transmission. There is a concern that if we only invest in one or
373 two testing interventions and remove others, we may not impact on HIV incidence and
374 indeed we may be doing harm. For example, investing solely in interventions that work for
375 urban gay men who use the internet may systematically fail to provide testing interventions
376 for men with low levels of health and digital literacy; amplifying health inequities. Embracing
377 the complexity and plurality of testing interventions, leads to the development of a
378 programmatic and systemic approach to HIV testing interventions. Subsequent research

379 questions focus on how best to use available evidence from specific interventions with clear
380 population parameters, and how best to offer combinations of a range of interventions
381 concurrently.

382

383 In Table 5 we summarise the key dimensions of HIV testing that we have identified within
384 the paper; these are not exhaustive. We hope that these will prove useful in retrospectively
385 considering the ways we describe HIV testing interventions and their effectiveness in order
386 to build useful knowledge for future service provision through evidence synthesis. Moreover,
387 we think these dimensions may also be useful for considering new ways of conceptualizing
388 future interventions and understanding the opportunities and limitations of current
389 interventions. We believe that better interventions can be developed and described if we
390 engage with this level of specificity, for example, rather than describing 'internet delivered
391 testing interventions' we can suggest 'using self tests to target those mid-sexual career men
392 who are seeking to test because of on-going risk behavior and who live in areas well served
393 by internet connections'. This is useful because it helps consolidate an evidence base but
394 also because it indicates who is likely to be excluded from engaging with the specified
395 intervention and encourages us to think about who may require alternative interventions.
396 For example, a complementary intervention may be needed that uses point of care testing
397 in primary care and targets those who are in need of persuasive interventions to test in
398 response to a 'one off' perceived high risk event or those who lack the material or
399 psychological resources to use an HIV self test kit. The dimensions facilitate an understanding
400 of the differences in the economic, legislative and cultural context of nations, states, or
401 provinces that also constrain the possible parameters of these dimensions.

402

403 **References**

- 404 1. Flowers, P. Wu, O. Lorimer, K., Ahmed, B. et al. The clinical effectiveness of individual behaviour change
405 interventions to reduce risky sexual behaviour after a negative HIV test in men who have sex with men (MSM):
406 systematic and realist reviews and intervention development. NIHR HTA journal in press
407
- 408 2. Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the
409 care continuum in the United States. *JAMA internal medicine*. 2015; 175:588-96.
410
- 411 3. Sullivan PS, Carballo-Dieguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, et al. Successes and challenges
412 of HIV prevention in men who have sex with men. *Lancet*. 2012;380(9839):388-99. Epub 2012/07/24
413
- 414 4. Conserve DF, Jennings L, Aguiar C, Shin G, Handler L, Maman S. Systematic review of mobile health behavioural
415 interventions to improve uptake of HIV testing for vulnerable and key populations. *Journal of Telemedicine and*
416 *Telecare*. 2016 Apr 6:1357633X16639186.
417
- 418 5. Estem KS, Catania J, Klausner JD. HIV Self-Testing: a Review of Current Implementation and Fidelity. *Current*
419 *HIV/AIDS Reports*. 2016 Apr 1;13(2):107-15.
420
- 421 6. Solorio R, Norton-Shelpuk P, Forehand M, Montañó D, Stern J, Aguirre J, Martinez M. Tu Amigo Pepe: Evaluation
422 of a Multi-media Marketing Campaign that Targets Young Latino Immigrant MSM with HIV Testing Messages.
423 *AIDS and Behavior*. 2016 Feb 5:1-6.
424
- 425 7. Davis, M, Frankis, J, Flowers, P et al. (2016) Location, safety and (non) strangers in gay men’s narratives on
426 ‘hook-up’ apps. *Sexualities* in press
427
- 428 8. Gardner, E. M., McLees, M. P., Steiner, J. F., del Rio, C., & Burman, W. J. (2011). The spectrum of engagement
429 in HIV care and its relevance to test-and-treat strategies for pre-vention of HIV infection. *Clinical Infectious*
430 *Diseases*, 52, 793–800. doi:10.1093/cid/ciq243
431
- 432 9. De Cock, K. and Johnson, A. (1998) From exceptionalism to normalisation: a reappraisal of attitudes and
433 practice around HIV testing. *BMJ* 1998;316:290 *BMJ* 1998; 316 doi:
434 <http://dx.doi.org/10.1136/bmj.316.7127.290> (Published 24 January 1998)
435
- 436 10. Marks, Gary; Crepaz, Nicole PhD; Senterfitt, J Walton PhD; Janssen, Robert S MD Meta-Analysis of High-Risk
437 Sexual Behavior in Persons Aware and Unaware They are Infected With HIV in the United States: Implications
438 for HIV Prevention Programs *JAIDS Journal of Acquired Immune Deficiency Syndromes*:1 August 2005 - Volume
439 39 - Issue 4 - pp 446-453
440
- 441 11. Bassett I, Regan S, Luthuli P, Mbonambi H, Bearnot B, Pendleton A, Robine M, Mukuvisi D, Thulare H, Walensky
442 R, Freedberg K, Losina E, Mhlongo B: Linkage to care following community-based mobile HIV testing compared
443 with clinic-based testing in Umlazi Township, Durban, South Africa. *HIV Med*. 2013;15:367–372
444
- 445 12. PHE presentation 2016
446
- 447 13. Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual
448 risk behavior: a meta-analytic review of published research, 1985-1997. *American journal of public*
449 *health*. 1999 Sep;89(9):1397-405.
450
- 451 14. Sonnenberg, Pam et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted
452 infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal) *The Lancet* ,
453 Volume 382 , Issue 9907 , 1795 – 1806
454

- 455 15. Flowers P, Knussen C, McDaid L, Li J (2013). Has testing been normalised?: An analysis of changes in barriers
456 to HIV testing among men who have sex with men between 2000 and 2010 in Scotland, UK: *HIV Medicine*,
457 Feb;14 (2):92-8. DOI: 10.1111/j.1468-1293.2012.01041.
458
- 459 16. Clifton, Soazig; Nardone, Anthony; Field, Nigel; Mercer, Catherine H.; Tanton, Clare; Macdowall, Wendy;
460 Johnson, Anne M.; Sonnenberg, Pam HIV testing, risk perception, and behaviour in the British population. *AIDS*:
461 27 March 2016 - Volume 30 - Issue 6 - p 943–952doi: 10.1097/QAD.0000000000001006
462
- 463 17. Deblonde J., De Koker P., Hamers F. F., Fontaine J., Luchters S., Temmerman M. (2010). Barriers to HIV testing
464 in Europe: A systematic review. *The European Journal of Public Health*, 20, 422–432. 10.1093/eurpub/ckp231
465
- 466 18. Wallace LA, Li J, McDaid LM. HIV prevalence and undiagnosed infection among a community sample of gay and
467 bisexual men in Scotland, 2005–2011: implications for HIV testing policy and prevention. *PloS one*. 2014 Mar
468 12;9(3):e90805.
469
- 470 19. Gilbert, M., Hottes, T., Lester, R. Gustafason, R., Krajden, M and Ogilvie, G. , Time since last negative HIV test
471 among men who have sex with men and people who use injection drugs in British Columbia, 2006-2011. *Can J*
472 *Public Health* 2014;105(1):e63-e68.
473
- 474 20. Hickson F, Tomlin K, Hargreaves J, Bonell C, Reid D, Weatherburn P. Internet-based cohort study of HIV testing
475 over 1 year among men who have sex with men living in England and exposed to a social marketing intervention
476 promoting testing. *Sexually transmitted infections*. 2015 Feb 1;91(1):24-30.
477
- 478 21. Williamson LM, Flowers P, Knussen C, Hart GJ (2009). HIV testing trends among gay men in Scotland, UK (1996-
479 2005): Implications for HIV testing policies and prevention. *Sexually transmitted infections*, 85(7), 487-8
480
- 481 22. Stephenson R, White D, Darbes L, Hoff C, Sullivan P. HIV testing behaviors and perceptions of risk of HIV
482 infection among MSM with main partners. *AIDS and Behavior*. 2015 Mar 1;19(3):553-60.
483
- 484 23. Martin, S., Young, I., Riddell, J., Hilton, S., McDaid, L., Flowers, P., and Gilbert, M. (2015) P68 Sexual health
485 literacy and men who have sex with men (msm): a scoping review of research literature. *Sexually Transmitted*
486 *Infections*, 91(Suppl), A38-A38. (doi:10.1136/sextrans-2015-052126.111)
487
- 488 24. Witzel, S Guise, A., Nutland, W., It Starts With Me: Privacy concerns and stigma in the evaluation of a
489 Facebook health promotion intervention. *Sexual Health* 2016; <http://dx.doi.org/10.1071/SH15231>
490
- 491 25. Akin M, Fernandez MI, Bowen GS, Warren JC. HIV risk behaviors of Latin American and Caribbean men who
492 have sex with men in Miami, Florida, USA. *Revista panamericana de salud publica = Pan American journal of*
493 *public health*. 2008;23(5):341-8. Epub 2008/05/31. 26.
494
- 495 26. Icard, L.D. (2008) Reaching African American men on the down low: sampling hidden populations:
496 implications for HIV prevention. *Journal of homosexuality*, 55, 93): 437-449
497
- 498 27. Martinez O, Wu E, Shultz AZ, Capote J, Lopez Rios J, Sandfort T, et al. Still a hard-to-reach population? Using
499 social media to recruit Latino gay couples for an HIV intervention adaptation study. *Journal of medical*
500 *Internet research*. 2014;16(4):e113. Epub 2014/04/26. 8.
501
- 502 28. Sullivan PS, Khosropour CM, Luisi N, Amsden M, Coggia T, Wingood GM, et al. Bias in online recruitment and
503 retention of racial and ethnic minority men who have sex with men. *Journal of medical Internet research*.
504 2011;13(2):e38. Epub 2011/05/17?
- 505 29. Garnett GPG, S. . HIV Prevention Cascades. *The Lancet HIV*. 2016;pending